Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abiraterone, abuse, Algeta, alleviation, alpha, Alpharadin, arm, arose, baseline, beta, blinding, broadly, CabOzantinibMET, carryover, CI, cohort, concomitant, consecutive, Cooperative, corroborated, Court, covenant, CRADA, CRPC, CTEP, daily, decrement, decrese, delta, discontinuted, docetaxel, endpoint, entirety, entry, error, ethically, EXAM, exploring, False, Fast, feedback, floor, footnote, fraud, Garland, hazard, hear, inAdvancedMedullary, IST, Kingdom, licensee, lt, median, mentioned, Merck, mg, mitoxantrone, modest, MSD, narcotic, ninety, Nodality, notably, notification, NRE, opioid, pain, palliation, partnership, persuasive, placebo, prednisone, remit, resolution, restrucuturing, rolling, Sanofi, scan, Scott, secondary, SPA, spent, successor, Supreme, symptomatic, teaching, theEXAM, tier, tiered, tivantinib, treasury, unclear, unconstitutional, unissued, unused, upcoming, usage, week, worst, XBRL
Removed:
accounted, activated, activation, antagonist, APA, ASCO, backup, bioavailability, borrowed, cellular, chaperone, chemical, chemotherapeutic, chronic, Concurrently, conferring, Connecticut, constitute, controlling, CRA, crop, cytokine, dasatinib, decreasing, diversity, division, Dow, downstream, EORTC, exhibited, facing, flexibility, function, GAAP, glioma, grow, Guilford, Hematology, imatinib, implement, inclusion, inhibiting, intolerant, leukemia, LIBOR, mTOR, mutant, natural, oral, outplacement, overexpression, owe, pharmacokinetic, platform, play, poor, potency, potent, potently, practice, progression, proliferation, prominent, promote, protein, PTEN, RAS, regression, resistance, resistant, restructure, role, RTK, selective, selectively, SRC, stability, synergistic, thought, toxicology, translation, tyrosine, upregulation, utility, xenograft
Filing tables
Filing exhibits
- 10-K Annual report
- 10.21 Offer Letter Agreement, Between Exelixis, Inc. and J. Scott Garland
- 10.26 Compensation Information for Non-employee Directors
- 10.83 Termination Agreement Between Exelixis, Inc. and Sanofi
- 10.91 Exclusive License Agreement Between Exelixis, Inc. and Merck
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification by the CEO and CFO As Required by Rule 13A-14(B) or 15D-14(B)
Related press release
EXEL similar filings
Filing view
External links